Business · 07/04/2000Updated: 10/17/2026 · 1 min read
FDA Announces Submission of Information Collection for OMB Review
Summary
The Food and Drug Administration (FDA) is requesting public comment on proposed changes to its process for reviewing New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs), as part of its ongoing efforts to streamline its regulatory processes.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →